Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lifted by Blueprint Investment Partners LLC

Blueprint Investment Partners LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 59.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,771 shares of the biopharmaceutical company’s stock after acquiring an additional 2,537 shares during the quarter. Blueprint Investment Partners LLC’s holdings in Gilead Sciences were worth $625,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new stake in Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last ninety days. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Up 1.1 %

Shares of NASDAQ:GILD opened at $107.08 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $133.35 billion, a P/E ratio of 289.41, a P/E/G ratio of 0.71 and a beta of 0.21. The stock’s 50-day moving average is $103.68 and its 200-day moving average is $93.85.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

A number of research firms recently commented on GILD. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Oppenheimer upped their price target on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.